Scinai Immunotherapeutics
SCNI
10 hedge funds and large institutions have $623K invested in Scinai Immunotherapeutics in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
1.72% less ownership
Funds ownership: 2.92% → 1.2% (-1.7%)
33% less funds holding
Funds holding: 15 → 10 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
97% less capital invested
Capital invested by funds: $21.1M → $623K (-$20.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$666K |
| 2 |
Two Sigma Investments
New York
|
+$327K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$266K |
| 4 |
Morgan Stanley
New York
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$96.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$12.6M |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$2.91M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$701K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$335K |
| 5 |
MA
Mutual Advisors
Omaha,
Nebraska
|
-$280K |
SCNI Hedge Fund Activity: Q4 2020 in Review
10 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2020, worth a combined $623K — down 97% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SCNI and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was State Street, adding an estimated $666K. The largest seller was Ibex Investors, exiting entirely with an estimated $12.6M sold.
- 10 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2020, down from 15 in Q3 2020.
- Funds reported $623K of Scinai Immunotherapeutics stock for Q4 2020, down 97% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q4 2020 and 7 closed out, a net change of -5 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2020 was State Street, an estimated $666K added.
- The largest Scinai Immunotherapeutics seller in Q4 2020 was Ibex Investors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2020.